What are the recommended antibiotics for treating skin and soft‑tissue infections in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Recommended Antibiotics for Skin and Soft Tissue Infections in Adults

The choice of antibiotic depends critically on whether the infection is purulent or nonpurulent, and whether it is mild (outpatient) or severe (hospitalized). This distinction determines both the likely pathogen and the appropriate empirical therapy 1, 2, 1, 2, 1.

Outpatient Management

Nonpurulent Cellulitis (No Drainage, No Abscess)

For typical cellulitis without purulent drainage, empirical therapy targeting β-hemolytic streptococci is the priority 1, 2, 1, 2, 1. The role of community-acquired MRSA (CA-MRSA) in nonpurulent cellulitis remains uncertain.

First-line oral options:

  • Penicillin (penicillin V or benzylpenicillin) for classic erysipelas 3
  • Cephalexin 500 mg four times daily 3
  • Dicloxacillin 500 mg four times daily 3
  • Cefazolin 1 g every 8 hours IV (if parenteral needed) 3

For penicillin-allergic patients (non-immediate hypersensitivity):

  • First-generation cephalosporins remain acceptable 3

For penicillin-allergic patients (immediate hypersensitivity):

  • Clindamycin 300-450 mg three times daily 1, 2, 1, 2, 3, 1, 3

Duration: 5-10 days, individualized based on clinical response 1, 2, 1, 2, 1

Critical caveat: If the patient fails to respond to β-lactam therapy or presents with systemic toxicity, add empirical MRSA coverage 1, 2, 1, 2, 1.

Purulent Cellulitis (Drainage/Exudate Without Drainable Abscess)

For purulent cellulitis, empirical CA-MRSA coverage is mandatory pending culture results 1, 2, 1, 2, 1. Empirical coverage for β-hemolytic streptococci is likely unnecessary in this setting.

First-line oral options for MRSA coverage:

  • Clindamycin 300-450 mg three times daily (A-II evidence) 1, 2, 1, 2, 1
  • Trimethoprim-sulfamethoxazole (TMP-SMX) 1-2 double-strength tablets twice daily (A-II evidence) 1, 2, 1, 2, 3, 1, 3
  • Doxycycline or minocycline 100 mg twice daily (A-II evidence) 1, 2, 1, 2, 3, 1, 3
  • Linezolid 600 mg twice daily (A-II evidence) 1, 2, 1, 2, 1

If dual coverage for both β-hemolytic streptococci AND CA-MRSA is desired:

  • Clindamycin alone (covers both) 1, 2, 1, 2, 1
  • TMP-SMX or tetracycline PLUS a β-lactam (e.g., amoxicillin) 1, 2, 1, 2, 1
  • Linezolid alone (covers both) 1, 2, 1, 2, 1

Duration: 5-10 days based on clinical response 1, 2, 1, 2, 1

Important pitfall: TMP-SMX and doxycycline have poor streptococcal coverage, so if streptococcal infection is suspected, add a β-lactam or use clindamycin/linezolid alone 1, 2, 1, 2, 1.

Cutaneous Abscesses

Incision and drainage (I&D) is the primary treatment 1, 2, 1, 2, 1. For simple abscesses, I&D alone is likely adequate.

Antibiotic therapy is recommended when:

  • Severe/extensive disease (multiple sites) or rapid progression with cellulitis
  • Signs of systemic illness
  • Comorbidities or immunosuppression
  • Extremes of age
  • Difficult-to-drain location (face, hand, genitalia)
  • Associated septic phlebitis
  • Lack of response to I&D alone 1, 2, 1, 2, 1

When antibiotics are indicated, use the same MRSA-active regimens as for purulent cellulitis above.

Hospitalized Patients with Complicated SSTI

For hospitalized patients with complicated SSTI (deeper infections, surgical/traumatic wounds, major abscesses, infected ulcers/burns), empirical MRSA coverage should be considered pending cultures 1, 2, 1, 2, 1.

First-line IV options:

  • Vancomycin 30 mg/kg/day in 2 divided doses (A-I evidence) 1, 2, 1, 2, 3, 1, 3
  • Linezolid 600 mg IV/PO twice daily (A-I evidence) 1, 2, 1, 2, 3, 1, 3
  • Daptomycin 4 mg/kg IV once daily (A-I evidence) 1, 2, 1, 2, 3, 1, 3
  • Telavancin 10 mg/kg IV once daily (A-I evidence) 1, 2, 1, 2, 1
  • Clindamycin 600 mg IV/PO three times daily (A-III evidence) 1, 2, 1, 2, 1

For hospitalized patients with nonpurulent cellulitis:

  • A β-lactam antibiotic (e.g., cefazolin) may be considered initially, with modification to MRSA-active therapy if no clinical response 1, 2, 1, 2, 1

Duration: 7-14 days, individualized based on clinical response 1, 2, 1, 2, 1

Necrotizing Fasciitis and Severe Infections

Urgent surgical debridement is paramount and takes precedence over antibiotics 4, 5. Empirical broad-spectrum therapy covering MRSA, streptococci, anaerobes, and gram-negatives is essential.

First-line regimens for mixed polymicrobial infections:

  • Piperacillin-tazobactam 3.37 g every 6-8 hours IV PLUS vancomycin 4, 5
  • Imipenem-cilastatin 1 g every 6-8 hours IV 4, 5
  • Meropenem 1 g every 8 hours IV 4, 5
  • Ertapenem 1 g daily IV 4, 5
  • Cefotaxime 2 g every 6 hours IV PLUS metronidazole 500 mg every 6 hours IV 4, 5

For streptococcal necrotizing fasciitis:

  • Penicillin 2-4 million units every 4-6 hours IV PLUS clindamycin 600-900 mg every 8 hours IV 4, 5
  • Clindamycin is critical as it suppresses toxin production 4, 5

For clostridial myonecrosis (gas gangrene):

  • Clindamycin 600-900 mg every 8 hours IV PLUS penicillin 2-4 million units every 4-6 hours IV 4, 5

Special Considerations

Impetigo

For limited lesions:

  • Mupirocin 2% topical ointment three times daily 1, 2, 1, 2, 3, 1, 3

For more extensive impetigo:

  • Dicloxacillin 250 mg four times daily 3
  • Cephalexin 250 mg four times daily 3
  • Clindamycin 300-400 mg three times daily 3
  • Amoxicillin-clavulanate 875/125 mg twice daily 3

Animal/Human Bites

Oral therapy:

  • Amoxicillin-clavulanate 875/125 mg twice daily (first-line) 5

IV therapy:

  • Ampicillin-sulbactam 1.5-3.0 g every 6-8 hours 5
  • Piperacillin-tazobactam 3.37 g every 6-8 hours 5

Preemptive antibiotics (3-5 days) are recommended for:

  • Immunocompromised or asplenic patients
  • Advanced liver disease
  • Preexisting edema
  • Moderate-severe injuries, especially hand/face
  • Injuries penetrating periosteum/joint capsule 5

Key Pitfalls to Avoid

  1. Do not use rifampin as single agent or adjunctive therapy for SSTI 1, 2, 1, 2, 1

  2. Obtain cultures from purulent SSTIs when treating with antibiotics, in severe infections, systemic illness, inadequate response to initial treatment, or concern for outbreak 1, 2, 1, 2, 1

  3. Clindamycin resistance: Be aware of potential cross-resistance with erythromycin-resistant strains and inducible resistance in MRSA 3. Use only if local clindamycin resistance rates are low (e.g., <10%) 1, 2, 1, 2, 1

  4. Bilateral cellulitis is rare - consider alternative diagnoses like venous stasis dermatitis or deep venous thrombosis 6

  5. Tetracyclines should not be used in children <8 years of age 1, 2, 1, 2, 1

References

6
Research

Skin and Soft Tissue Infections.

American family physician, 2026

Related Questions

What is an appropriate oral antibiotic for an uncomplicated community‑acquired skin infection in an adult without drug allergies?
What is the appropriate management of a skin and soft tissue infection of a colloidal scar in the suprapubic area?
What intravenous antibiotic regimen should be started for a hospitalized patient with a severe skin and soft tissue infection, including dosing, alternatives, and monitoring?
What are the IDSA guidelines for the diagnosis and treatment of skin and soft‑tissue infections?
What is the appropriate management for a skin and soft tissue infection with purulent discharge over a suprapubic surgical scar?
Can calcium channel blockers be prescribed to patients with an ascending aortic aneurysm?
What is the optimal management of Raynaud's phenomenon in a patient with an ascending aortic aneurysm?
How should white discoloration of the lips be evaluated and managed?
What is the prognosis and likelihood of survival for a 37‑year‑old man with hypoxic‑ischemic brain injury after cardiac arrest, who has been on mechanical ventilation for approximately four weeks, now only opens his eyes to pain, and whose MRI demonstrates extensive symmetrical diffusion restriction in the parieto‑occipital cortex and deep basal ganglia?
What is the recommended albendazole dosing for ascariasis in adults and children of various weights?
What is the appropriate vitamin D syrup dose for a 6-year-old child to be administered three times daily?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.